Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | Chief Financial Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,334 |
Reported balance
After 2024-01-02 transaction · row 1
1 source rowRow 1 · 2024-01-02 · Tax withholding · Disposed 382 · Balance 86,334 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IXYS, LLC
Report date January 17, 2018 · Filed January 18, 2018
Section 16 reporting ended · disclosed 2018-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 1
1 source rowRow 1 · 2018-01-17 · Disposition to issuer · Disposed 5,172 · Balance 0 F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.83 · Expires 2024-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2025-08-28 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2026-08-26 | Direct | 0 |
Reported balance
After 2018-01-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option. F3: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 25, 2017 by and among the Issuer, Littelfuse, Inc. ("Littelfuse"), and Iron Merger Co., Inc. (as amended by Amendment No. 1, dated December 4, 2017, by and among the Issuer, Littelfuse, Iron Merger Co., Inc. and IXYS Merger Co., LLC) (the "Merger"). Each share of Issuer common stock held by the reporting person was cancelled in the Merger and converted into the right to receive, at the election of the holder and subject to proration, (i) $23.00 in cash per share, without interest and less any applicable withholding taxes or (ii) 0.1265 shares of Littelfuse common stock.
F2: Disposed of pursuant to the Merger. Each outstanding and unexercised option to purchase the Issuer's common stock held by the non-employee directors of the Issuer was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product of (x) the excess, if any, of the product of (i) 0.1265 and (ii) $210.77, which is the closing price per share on January 17, 2018 of Littlefuse common stock as reported on the Nasdaq Global Select Market, over the exercise price per share of such option and (y) the number of shares subject to such option.
F3: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2021 Filed Jul 23, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-007788 · marketforms-53440.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,415 Underlying: Common Stock · 5,000 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,000 | $119.75 | $598,750.00 |
DisclosureSEC source: 0001214659-21-007788 · marketforms-53440.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,475 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,000 | $26.66 | $133,300.00 |
DisclosureSEC source: 0001214659-21-007788 · marketforms-53440.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 19:32 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 257 | $131.48 | $33,790.36 |
DisclosureSEC source: 0001214659-21-007317 · marketforms-53256.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,475 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-21-006434 · marketforms-53098.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,330 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,000 | $103.38 | $827,040.00 |
DisclosureSEC source: 0001214659-21-006434 · marketforms-53098.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,732 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 8,000 | $11.59 | $92,720.00 |
DisclosureSEC source: 0001214659-21-006434 · marketforms-53098.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-006242 · marketforms-52990.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,415 Underlying: Common Stock · 6,000 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,000 | $110.00 | $660,000.00 |
DisclosureSEC source: 0001214659-21-006242 · marketforms-52990.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,732 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,000 | $26.66 | $159,960.00 |
DisclosureSEC source: 0001214659-21-006242 · marketforms-52990.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 17:15 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $97.75 | $100,389.25 |
DisclosureSEC source: 0001214659-21-005867 · marketforms-52897.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,732 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 17:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 275 | $133.12 | $36,608.00 |
DisclosureSEC source: 0001214659-21-004544 · marketforms-52331.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,759 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-21-004503 · marketforms-52309.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,330 Underlying: Common Stock · 5,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,000 | $133.47 | $667,350.00 |
DisclosureSEC source: 0001214659-21-004503 · marketforms-52309.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,034 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 17:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,000 | $11.59 | $57,950.00 |
DisclosureSEC source: 0001214659-21-004503 · marketforms-52309.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 18:32 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 256 | $122.20 | $31,283.20 |
DisclosureSEC source: 0001214659-21-003954 · ownership.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,034 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 10:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 256 | $122.20 | $31,283.20 |
DisclosureSEC source: 0001214659-21-004000 · marketforms-52193.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,034 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-003815 · marketforms-52155.xml · derivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,415 Underlying: Common Stock · 6,000 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,000 | $110.00 | $660,000.00 |
DisclosureSEC source: 0001214659-21-003815 · marketforms-52155.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,290 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 16, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 16:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,000 | $26.66 | $159,960.00 |
DisclosureSEC source: 0001214659-21-003815 · marketforms-52155.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:56 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $150.81 | $154,881.87 |
DisclosureSEC source: 0001214659-21-002300 · marketforms-51554.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,290 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:49 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 280 | $190.64 | $53,379.20 |
DisclosureSEC source: 0001214659-21-000829 · marketforms-51259.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,171 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:54 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 267 | $141.29 | $37,724.43 |
DisclosureSEC source: 0001214659-21-000149 · marketforms-50799.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,451 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,992 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · derivative · entry 10 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,748 Underlying: Common Stock · 5,992 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,008 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · derivative · entry 9 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,330 Underlying: Common Stock · 14,008 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,309 | $152.17 | $351,363.53 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,700 F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $151.90 to $152.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,600 | $151.37 | $393,557.06 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,009 F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $150.75 to $151.68 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,522 | $149.62 | $227,714.03 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,609 F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $149.32 to $149.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,386 | $148.69 | $949,508.16 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 5 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $148.33 to $149.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,501 | $147.87 | $813,419.12 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,517 F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $147.33 to $148.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,700 | $146.66 | $249,327.78 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,018 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $146.42 to $146.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 5,992 | $23.33 | $139,793.36 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 14,008 | $11.59 | $162,352.72 |
DisclosureSEC source: 0001214659-20-010388 · marketforms-50626.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 16, 2020 17:48 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,368 | $148.69 | $946,831.81 |
DisclosureSEC source: 0001214659-20-010491 · marketforms-50645.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,149 F1 · shares: The Form 4 originally filed on 12/14/2020 incorrectly reported 6,386 shares sold. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $148.33 to $149.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 17:56 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 967 | $115.56 | $111,746.52 |
DisclosureSEC source: 0001214659-20-009878 · marketforms-50160.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,718 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 16:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,034 | $85.97 | $88,892.98 |
DisclosureSEC source: 0001214659-20-008876 · marketforms-49866.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,685 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 16:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-20-007795 · marketforms-49661.xml · derivative · entry 4 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,415 Underlying: Common Stock · 20,000 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is immediately exercisable. 20% of the shares subject to the option vested on October 31, 2019, and 1/60th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 16:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,000 | $66.42 | $132,848.60 |
DisclosureSEC source: 0001214659-20-007795 · marketforms-49661.xml · nonDerivative · entry 3 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,719 F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $66.37 to $66.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 16:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 18,000 | $65.90 | $1,186,275.60 |
DisclosureSEC source: 0001214659-20-007795 · marketforms-49661.xml · nonDerivative · entry 2 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,719 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.37 to $66.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 16:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 20,000 | $26.66 | $533,200.00 |
DisclosureSEC source: 0001214659-20-007795 · marketforms-49661.xml · nonDerivative · entry 1 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,589 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · derivative · entry 16 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,415 Underlying: Common Stock · 10,589 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option is immediately exercisable. 20% of the shares subject to the option vested on October 31, 2019, and 1/60th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 59,411 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · derivative · entry 15 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,338 Underlying: Common Stock · 59,411 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on April 23, 2019, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 301 | $64.24 | $19,336.75 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 13 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,719 F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $64.24 to $64.26 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,137 | $63.70 | $199,836.00 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 12 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,020 F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $63.15 to $64.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,151 | $62.66 | $448,080.23 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 11 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,157 F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $62.14 to $63.12 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 10,589 | $26.66 | $282,302.74 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 10 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,479 | $64.13 | $607,920.50 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 9 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,719 F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $64.00 to $64.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 17,477 | $63.44 | $1,108,728.65 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 8 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,198 F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $63.00 to $64.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 32,455 | $62.61 | $2,031,887.47 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 7 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,657 F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $62.01 to $62.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 59,411 | $11.59 | $688,573.49 |
DisclosureSEC source: 0001214659-20-007754 · marketforms-49643.xml · nonDerivative · entry 6 THORBURN JAMES M · CIK 0001252038 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.